[{"address1": "4960 Peachtree Industrial Boulevard", "address2": "Suite 240", "city": "Norcross", "state": "GA", "zip": "30071", "country": "United States", "phone": "678 620 3186", "website": "https://galectintherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.", "fullTimeEmployees": 15, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joel  Lewis CPA", "age": 54, "title": "President, CEO & Director", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 987039, "exercisedValue": 0, "unexercisedValue": 12600}, {"maxAge": 1, "name": "Mr. Jack W. Callicutt CPA", "age": 57, "title": "CFO, Treasurer & Corporate Secretary", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 572205, "exercisedValue": 0, "unexercisedValue": 9000}, {"maxAge": 1, "name": "Dr. Khurram  Jamil M.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 547347, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Tritt J.D.", "title": "General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeff  Katstra", "title": "Head of CMC & Pharmaceutical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Beth  Knowles", "title": "Executive Assistant & Officer Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 7, "shareHolderRightsRisk": 3, "overallRisk": 5, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.11, "open": 2.11, "dayLow": 2.11, "dayHigh": 2.27, "regularMarketPreviousClose": 2.11, "regularMarketOpen": 2.11, "regularMarketDayLow": 2.11, "regularMarketDayHigh": 2.27, "payoutRatio": 0.0, "beta": 0.545, "forwardPE": -1.2916667, "volume": 224814, "regularMarketVolume": 224814, "averageVolume": 583636, "averageVolume10days": 2665900, "averageDailyVolume10Day": 2665900, "bid": 1.61, "ask": 2.81, "bidSize": 1, "askSize": 1, "marketCap": 137342784, "fiftyTwoWeekLow": 0.73, "fiftyTwoWeekHigh": 3.9, "fiftyDayAverage": 1.5386, "twoHundredDayAverage": 1.84285, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 236765248, "profitMargins": 0.0, "floatShares": 44087019, "sharesOutstanding": 63291600, "sharesShort": 8954593, "sharesShortPriorMonth": 8667591, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.1415, "heldPercentInsiders": 0.30435, "heldPercentInstitutions": 0.15777999, "shortRatio": 56.27, "shortPercentOfFloat": 0.2374, "impliedSharesOutstanding": 63834900, "bookValue": -1.809, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -45308000, "trailingEps": -0.72, "forwardEps": -1.68, "lastSplitFactor": "1:6", "lastSplitDate": 1332460800, "52WeekChange": -0.07456142, "SandP52WeekChange": 0.12632763, "quoteType": "EQUITY", "currentPrice": 2.17, "targetHighPrice": 6.0, "targetLowPrice": 6.0, "targetMeanPrice": 6.0, "targetMedianPrice": 6.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 7431000, "totalCashPerShare": 0.117, "totalDebt": 108428000, "quickRatio": 0.067, "currentRatio": 0.084, "returnOnAssets": -1.43578, "freeCashflow": -26145250, "operatingCashflow": -37351000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "GALT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "REGULAR", "corporateActions": [], "regularMarketTime": 1751394918, "exchange": "NCM", "messageBoardId": "finmb_1065415", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.8436105, "regularMarketPrice": 2.17, "shortName": "Galectin Therapeutics Inc.", "longName": "Galectin Therapeutics Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1031146200000, "regularMarketChange": 0.06000018, "regularMarketDayRange": "2.11 - 2.27", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 583636, "fiftyTwoWeekLowChange": 1.44, "fiftyTwoWeekLowChangePercent": 1.9726027, "fiftyTwoWeekRange": "0.73 - 3.9", "fiftyTwoWeekHighChange": -1.73, "fiftyTwoWeekHighChangePercent": -0.44358975, "fiftyTwoWeekChangePercent": -7.4561415, "earningsTimestamp": 1747310402, "earningsTimestampStart": 1754915400, "earningsTimestampEnd": 1755261000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.72, "epsForward": -1.68, "fiftyDayAverageChange": 0.6314001, "fiftyDayAverageChangePercent": 0.41037315, "twoHundredDayAverageChange": 0.3271501, "twoHundredDayAverageChangePercent": 0.177524, "priceToBook": -1.1995578, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "cryptoTradeable": false, "displayName": "Galectin Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-01"}]